Introduction
Gene therapy vectors derived from lentiviruses (lentivectors) raise specific safety, ethical, and public health anxieties beyond those of more conventional gene delivery systems. They mirror concerns that were raised in the development of retroviral vectors, but which need to be reconsidered in light of the novel properties of lentivectors and the accumulation of scientific and clinical knowledge since that time. Possibilities include (i) the generation of replication competent lentiviruses (RCLs) during vector production due to recombination of vector plasimds or in vivo due to mobilization of vector proviral DNA by infectious retroviruses such as human immunodeficiency virus (HIV); (ii) insertional mutagenesis due to lentivector proviral DNA integrations, potentially leading to oncogenesis; (iii) germline alteration and transmission of transgene to offspring; and (iv) the dissemination of new lentiviruses beyond the patient. To date, in no country have authorities formally approved the use of lentivectors for clinical research.
The Gene Therapy Advisory Committee (GTAC) considers the acceptability of all proposals to conduct gene therapy in the United Kingdom based on ethical concerns, practical issues, and scientific merit. As part of its responsibilities, GTAC also examines new and emerging trends in gene therapy research and advises ministers on developments in gene therapy and their implications. GTAC held a forum in London in March 2002 to consider the benefits and risks of lentiviral vectors, as part of its 'horizon-scanning' activity. Those discussions are presented here.
Discussion
What do lentiviral vectors newly offer to the field of gene therapy?
Unlike other retroviruses, lentivectors do not necessarily require cell division for proviral integration and productive infection 1 (cf. Miller et al
2
) and so offer a gene delivery method that does not need growth factor administration to induce cell proliferation in cells transduced ex vivo. Additionally, lentivectors are sufficiently robust for in vivo administration, potentially facilitating the transduction of cells that would not be amenable by other gene therapy vectors. When appropriately pseudotyped, lentiviral vectors can transduce stem, dendritic, T-cells, and neurons. 3 Lentiviruses also transduce cells with high efficiency and stability of transgene expression. Hence, one compelling reason for the use of lentivectors is that they may provide a vehicle for the long-term in vivo clinical management of chronic diseases, such as Parkinson's disease. 4 
Previous experiences with retroviral vectors
Many of the questions on lentivector safety can be framed with reference to previous retroviral studies. ' Gold Standard' principles for murine oncoretroviral vector manufacture have already been established, as have assays for the testing of Replication Competent Retroviruses (RCRs). 5 At the time of GTAC'S forum in March 2002 no cancers had been linked to administration of oncoretroviral vectors or oncoretroviral vector-transduced cells in gene therapy patients. However, since then, in one patient a case of uncontrolled lympho-proliferation has been associated with the administration of a gene therapy retroviral vector [http://agmed.sante.gouv.fr/htm/10/filcoprs/ indco.htm]. In addition, a study in mice has indicated that murine bone marrow cells transduced with a Moloney murine leukaemia virus-based retroviral vector containing a transgene encoding a truncated form of low-affinity nerve growth factor receptor (dLNGFR) caused leukaemia. 6 The leukaemic cells contained the vector integrated by the Evi1 gene, a potential mutagenic 'hit' that by itself, or combined with postulated disruption of intracellular signalling pathways by dLNGFR, appeared necessary for oncogenic events. In primate studies, lymphomas have occurred from administration of high titres of RCRs to immunosuppressed monkeys. 7, 8 In humans, HIV integration may be responsible for some lymphomas. [9] [10] [11] [12] Insertional mutagenesis and oncogenesis Lentiviruses typically insert into host DNA as a single non-rearranged copy. It is unknown how many integration events yield the desired level of transgene expression. However, up to 20 insertions can be detected in any one cell. 13 Integration is known to trigger DNA repair mechanisms. Retroviral infection can also result in the generation of non-productive, 'dead-end' circular molecules. These may, in themselves, be toxic to the cell. [14] [15] [16] There appears to be no sequence specificity for integration by the retroviral agents used in current vector systems, although the structure of chromatin may play a role. Retroviral proviral DNA integration following infection with RCRs clearly has the potential to cause oncogenic events in animals, particularly in relation to haematological malignancies. As mentioned, one study in mice has also shown that a replication-deficient oncoretroviral vector is associated with leukaemia development. 6 However, pre-clinical rodent studies may not provide reliable predictions on the insertional mutagenesis/oncogenesis issue for clinical administrations of lentivectors or lentivector-transduced cells, as the number of events required for transformation could be less than in humans, perhaps due to differences in telomerase regulation. 17 In some haematological malignancies, a relatively minor number of mutagenic events, perhaps as low as three, is required for complete transformation. For other cancers, up to eight may be necessary. 18 Cell types may have differential potential for oncogenesis, for example, haematopoetic cells versus cells of solid tumours. Although numerous alterations of the coding and cis-acting sequences have been made in third-generation lentivectors, a central component in all of these systems is the LTR. This may itself contribute to the oncogenic potential of some retroviruses. 19 For the longer term, it may be useful to establish a database of retroviral integration sites from the genomes of gene therapy patients to determine definitively whether there are preferential integration sites and further characterize the safety profile of these vectors. These data could be incorporated into the outcome of long-term monitoring of patients' health. 20 Ultimately, such long-term monitoring of gene therapy patients may represent the only reliable way to assess the oncogenic potential of lentivectors in humans.
Lentivector design and production
Lentivectors are generated using a 'split-component' production system, the overall objective being to make each component less and less complete in function, to the point where infectious viral particles can only be produced in the packaging cell and not from the final vector preparation. Typically, producer cell lines are transfected with (i) the vector plasmid, containing the therapeutic payload, lentiviral LTRs for host cell integration and perhaps the Rev-responsive element (RRE) for most efficient vector production; (ii) a plasmid encoding the gag and pol viral structural genes, in order to supply reverse transcriptase and integration functions for the therapeutic vector particles; and (iii) plasmids encoding envelope proteins for the therapeutic viral particles and perhaps Rev protein. Other strategies for split vector systems have been designed whereby genetic elements have been inserted into helper plasmids to transcriptionally partition structural and envelope helper components. None of the starter plasmids are, by themselves, capable of functioning as autonomous lentiviruses. In addition, most accessory genes have been removed during the process. Only the therapeutic vector contains the packaging signal and thus, in theory, infectious particles should contain only the envisaged therapeutic payload. Typically, the env gene encoding the Gglycoprotein from vesicular stomatitis virus (VSV-G) is used. 21 Such pseudotyping of therapeutic vectors alters the native tropism of lentiviral vectors to allow infection of a broad range of host cell types. The principal concern rests on the chance of recombination between the splitcomponent sequences at the DNA or RNA level. 22 The risk of such events can be minimized to apparently negligible levels, but can never be eliminated. Apart from lack of overt sequence homology between plasmids, codon usage can be further optimized to provide an additional barrier to recombination. 23 The net result of such engineering is that multiple recombination events would be required to produce infectious RCL.
In theory, plasmids with gag, pol or VSV-G env could be packaged into viral particles. Cross-packaging of the therapeutic vector by other retroviruses and of other retroviruses by the vector should occur at demonstrably low levels. Conditional packaging systems are worth exploring. 24 These could include dependence, for example, on synthetic transfer RNA; or packaging constructs using a heterologous promoter only capable of function in producer cell lines.
Self-inactivating (SIN) vectors are deleted within the 3 0 LTR. 25 This allows SIN lentivectors to productively infect and integrate into target cell populations, but generation of proviral transcripts is blocked. Hence, SIN vectors may be a sensible precaution, as they are less likely to be mobilized by other RCLs. However, SIN vectors are difficult to manufacture and although phase I trials would be unaffected because of the inherent need for less material, larger scale endeavours could be hampered by an insistence on their use. Imposing restrictions on lentivector design flexibility at this stage may negatively impact this area of research.
While it seems wise to use the same vector preparation in both patients and pre-clinical animal studies, vectors with human gene promoters may behave significantly differently in animal hosts. Because lentivectors are Lentiviruses in gene therapy JB Connolly manufactured in eukaryotic cells, the level of contamination of the viral envelope with producer cell membrane molecules should be considered. Finally, viral particle number should be estimated by immunoassays based on Gag (for example, p24 Gag for HIV-1, where 1 pg of p24 Gag corresponds to 12 000 physical particles), Pol (PERT assays) or quantitative immunostaining methods, if available. These assessments do not distinguish between full (viral RNA genome-containing) and empty particles. Full, potentially bio-active, particles may be estimated by quantitative PCR on lentiviral genomes. Both particle number and in vitro potency (as measured by integration capacity or by functional assay of transgene product) should be estimated in each lentivector lot, so that a consistent product for ex vivo transductions can be achieved. In the case of in vivo applications, this would allow doses to be (i) accurately administered and (ii) properly standardized across studies.
Replication competent lentiviruses
The generation of RCLs in lentivector gene therapy trials is the greatest safety preoccupation of the field. RCLs could occur during manufacture of lentivectors or in patients via mobilization by infectious retroviruses, such as during parallel infection with HIV-1 or HIV-2. Most endogenous retroviral sequences in the human genome have large deletions and so cannot produce infectious virus, but the possibility that retroviral function could be supplied in trans or that the vector genome could recombine with human endogenous oncoretroviral sequences merits consideration. Removal of sequence homology in split-component systems reduces the risk during lentivector production. Experience from other retroviral vector studies suggests that any RCLs could be predicted from triple recombination product between vector, packaging plasmid, and env-containing plasmids. Although other envelopes are being explored, 26 VSV-G is currently the preferred envelope choice in most lentivectors. As VSV-G confers broad host cell range, carryover of VSV-G env DNA or mRNA sequences into vector preparations should be minimized by cogent manufacturing and downstream purification strategies. It is worth noting that the presence of a high concentration of vector material can cause interference in the detection of RCLs. Because all RCLs will have Gag/Pol (most likely, system-derived), measurements of polymerase activity, such as product-enhanced reverse transcriptase (PERT) assays, are to be encouraged. 27, 28 Aliquots from the viral lot can be chemically disrupted and a standard template for reverse transcriptase supplied to the solution. In the presence of Pol activity, cDNA is generated and a PCR reaction amplifies this sequence. These assays can be highly sensitive, where the detection of 10-100 Pol-positive particles is possible. However, it is undesirable to generate a lentivirus encoding VSV-G and Gag/Pol simply to calibrate these assays or to monitor RCL infectivity assays, since such a 'positive control' virus could itself be pathogenic. However, alternative approaches should be taken to validate the sensitivity of these assays.
The probability of recombination after transient transfection with three plasmids is much higher than the probability of recombination in stable producer cell lines containing single-copy cassettes with integrated elements. This is so provided that superinfection is not occurring to a significant extent in the long-term culture of the producer cells, as can happen using the VSV-G envelope. Whilst stable cell lines are highly desirable, for phase I studies, reliable, validated transiently transfected production systems may prove acceptable.
Standard tests for RCL in vector preparations involve a variety of in vitro infectivity-type assays, usually employing some tissue culture amplification procedures followed by measurement of physical, biochemicals, or biological parameters indicative of RCL propagation. 29 These could include p24 Gag measurements, enzyme marker rescue or rescue of cell proliferation. In addition, RCL genomes can be measured by quantitative RCR techniques assuming that appropriate primers are available. There are opportunities for RCL generation in vivo, but any RCL that arises will have an Env different from the VSV-G of the lentivectors. For example, if the vector genome is mobilized by HIV-1, it will have HIV-1 Env. Such RCLs only infect human cells and therefore there can be difficulties in establishing appropriate animal model systems. Immunodeficient rodents, such as SCIDhu mice, engrated with human haematolymphoid cells, may be suitable for checking the transmissability of RCLs in vivo. 30 Finally, patients should be monitored for vector mobilization. It is worth remembering that the long-term persistence of proviral DNA could result in RCL generation at any point in the patient's future.
Safety and ethics for HIV-based lentivectors
The biology and pathogenesis of HIV is well-studied. This offers both advantages and disadvantages in the use of HIV-based lentivectors. The use of HIV-based vectors in HIV-negative individuals may result in their partial seroconversion, although this could be distinguished from an actual HIV-1 infection. In HIV-infected patients, no new HIV viral material would be introduced from HIV-lentivectors. However, should an HIV-negative individual become infected with wild-type HIV during the course of a lentivector study, there could be ambiguity as to the perceived source of infection, although the origin of the infecting virus could be traced to an exogenous virus in such a case. This would need to be given careful consideration prior to research proposals. Finally, in HIV patients, mobilization of the therapeutic vector is possible. However, since any gene therapy patient could become HIV infected during a trial, arguments for and against the exclusion of HIV-positive patients would need to be considered carefully.
Germline transmission
The consequences of potential germline alterations via retroviral vectors remain unknown. The risk of fertilization from a transduced germ cell appears to be vanishingly low, but remains unquantified. Apart from vector integration, therapeutic gene expression that may be beneficial in one context could be deleterious another, such as during embryogenesis. Thalidomide and other current cancer chemotherapies raise similar issues for patient reproduction. Importance rests on the nature of the patient group. Many trial populations are restricted to those beyond the age of reproduction. However, the use of barrier contraception should remain a requirement for entry into gene therapy trails. It is feasible to monitor both sperm and ova for the presence of vector material, 
Adverse events
Lentivectors do not raise any new specific issues with regard to 'short-term' adverse event reporting and patient monitoring. Although systems are primarily designed to detect effects from therapeutic payloads, tumour progression or the appearance of new malignancies may be detected by pre-existing adverse eventreporting mechanisms. Long-term monitoring of patients is the most robust method for the detection of adverse events caused by insertional mutagenesis.
HIV, FIV, and EIAV: do we need more than one type of lentivector?
There are reasons, other than commercial, to proceed with different types of lentivector. 31, 32 Each type may offer unique advantages, for example, in tropism and cell-infectivity range. The role of HIV as a human immune system pathogen is well-delineated. Nonprimate lentiviruses have no known human pathogenicity but, importantly, are less well understood. The absence of data does not indicate the absence of effect and pathogenic features of non-primate lentiviruses would probably only be revealed by clinical study. Other factors that may influence vector choice are differential (i) toxicities of viral gene products from and (ii) host immune responses to the various lentiviral vectors. It is also worth noting that there are non-dividing cells that are not susceptible to infection by certain lentiviruses. For example, HIV-vectors do not infect a sub-population of haematopoietic stem cells. Thus, the pursuit of multiple vector types should eventually allow the targeting of a broader spectrum of cells.
Conclusions
The use of lentiviruses raises issues for patient safety, public health, and the public perception of gene therapy. Although GTAC cannot currently offer prescriptive advice to researchers on the use of lentivectors, many of the issues discussed herein will form the basis of any lentiviral protocol assessment. Investigators will also need to consider the implications of lentivector studies for research staff, for example, in the case of needle-stick injury and seroconversion. Given the unknown risks associated with lentiviral administration, compelling reasons justifying the choice of vector, the patient group, including immune system status, and the approach (ex vivo versus in vivo) will be required. These will be over and above the requirements for protocols involving vectors with established clinical safety track records. In addition, appropriate measurements of lentivector infectious particles, stringent quality control for RCLs, and precautions against and measurements for the mobilization of other retroviruses in patients will be necessary. Due account will have to be taken of the risks of interaction with HIV or other retroviral elements in research subjects. A risk-benefit analysis for each lentivector study should be carried out beforehand. The lack of patient safety data means that risks are likely to weighted more heavily than benefits. Investigators wishing to conduct lentiviral trials are encouraged to contact the secretariat of their national gene therapy supervisory body for discussions prior to any formal protocol submission. In GTAC's and the Department of Health's assessments of lentiviral vectors, the 'Precautionary Principle' will be invoked. 33 
